COX-2 selective inhibitor is a form of
non-steroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2,
COX-2, an
enzyme responsible for
inflammation and
pain. Targeting selectivity for COX-2 reduces the risk of
peptic ulceration, and is the main feature of
celecoxib,
rofecoxib and other members of this drug class. After several COX-2 inhibiting drugs were approved for marketing, data from clinical trials revealed that COX-2 inhibitors caused a significant increase in heart attacks and strokes, with some drugs in the class having worse risks than others. Rofecoxib (commonly known as
Vioxx) was taken off the market in 2004 because of these concerns and celecoxib and traditional NSAIDs received
boxed warnings on their labels.